Associated Feature — Nipple Involvement

Known malignancy or suspicious enhancement directly involves and is contiguous with the nipple.

Definition

  • Enhancement extends from a known tumor into and involves the nipple and/or nipple-areolar complex (NAC)
  • To qualify: must have definitive abnormal enhancement of the nipple — not just proximity or adjacent tumor
  • The abnormal enhancement must be contiguous with the underlying lesion, demonstrating a direct pathway of tumor extension
  • Isolated nipple enhancement without a contiguous breast lesion should raise suspicion for Paget disease rather than direct tumor invasion

Imaging Appearance

T1-Weighted (Pre-contrast)

  • Normal nipple appears as a low-to-intermediate signal structure
  • Tumor extending into the nipple may show loss of normal architecture and obscuration of the normal nipple contour

T2-Weighted

  • Normal nipple is low signal on T2W imaging
  • Involved nipple may show increased T2 signal indicating edema or tumor infiltration
  • Associated periareolar skin thickening or edema may be present

Post-contrast (Dynamic CE-MRI)

  • Abnormal asymmetric or mass-like enhancement extending from the tumor to the nipple
  • Enhancement may be continuous (trackable from tumor to nipple) or appear as a separate focus within the nipple connected by enhancing tissue
  • Kinetic curve of nipple enhancement typically mirrors the underlying malignancy (washout or plateau)
  • Subtraction images and MIP reconstructions are particularly helpful to trace the enhancing pathway from tumor to nipple

DWI

  • Restricted diffusion within the nipple on high b-value images supports malignant involvement
  • ADC values in the involved nipple are typically low, concordant with the primary tumor

Important Distinction — Normal vs Abnormal Nipple Enhancement

  • Normal nipples typically enhance symmetrically on bilateral MRI
  • Normal nipple enhancement may be asymmetric, sometimes related to nipple inversion or prior surgery
  • Asymmetric nipple enhancement alone does NOT equal nipple involvement
  • Key discriminator: abnormal nipple enhancement is contiguous with a known lesion or demonstrates suspicious morphologic and kinetic features in isolation

Board Pearl

Always compare nipple enhancement bilaterally. Symmetric enhancement is almost always benign. Unilateral or asymmetric enhancement that is contiguous with a mass or demonstrates washout kinetics warrants concern for tumor involvement.

Differential Diagnosis

EntityKey Distinguishing Features
Direct tumor extensionContiguous enhancing pathway from mass to nipple; most common cause of nipple involvement
Paget diseaseIsolated nipple/areolar enhancement ± underlying DCIS/invasive cancer; clinical eczematous changes
Nipple adenomaBenign papillomatous proliferation; well-circumscribed enhancement confined to nipple
Subareolar abscessRim-enhancing fluid collection; clinical erythema, tenderness; often periareolar
Benign nipple inversionAsymmetric enhancement with retracted nipple; no suspicious mass or kinetics
Post-surgical / post-radiation changesHistory-dependent; diffuse enhancement without discrete mass morphology

Clinical Significance

  • Surgical planning: Nipple involvement is a contraindication to nipple-sparing mastectomy (NSM)
  • Tumor-to-nipple distance (TND) of <1 cm on MRI is associated with higher risk of occult nipple involvement at pathology
  • Pre-operative MRI assessment of nipple involvement has high negative predictive value — a normal-appearing nipple on MRI reliably excludes involvement
  • Positive predictive value is moderate; biopsy confirmation (retroareolar frozen section) is standard before definitive surgery
  • Reporting nipple involvement changes the surgical approach and must be explicitly stated in the radiology report

Board Pearl

Paget disease can present as isolated nipple enhancement with no or minimal underlying breast findings on MRI. Always consider Paget disease when there is abnormal nipple enhancement, especially with clinical nipple changes (eczema, crusting, erosion). Up to 90% of Paget disease cases have an underlying carcinoma (DCIS or invasive).

Pitfalls

  • Over-calling proximity as involvement: A mass near the nipple is NOT the same as nipple involvement — enhancement must extend into the nipple itself
  • Ignoring normal asymmetric enhancement: Benign asymmetric nipple enhancement (especially with nipple inversion) can mimic involvement; compare with contralateral side and correlate clinically
  • Missing Paget disease: Isolated nipple enhancement without a breast mass is easy to dismiss — always correlate with clinical exam for skin changes
  • Motion artifact: The nipple is prone to motion artifact on dynamic sequences, which can obscure or simulate abnormal enhancement; confirm on multiple sequences and planes
  • Inadequate subtraction images: Subtle nipple enhancement may only be apparent on subtraction or MIP images — always review these reconstructions

Board Pearl

Tumor-to-nipple distance (TND) < 1 cm on MRI is the most commonly used threshold for predicting occult nipple involvement at pathology and determining nipple-sparing mastectomy eligibility. Always measure and report TND when mastectomy is being considered.

Reporting Recommendations

  • Explicitly state whether the nipple is involved, threatened (tumor within 1 cm), or uninvolved
  • Describe the pathway of enhancement from tumor to nipple when involvement is suspected
  • Note any skin thickening or areolar enhancement that may accompany nipple involvement
  • Compare with the contralateral nipple for symmetry assessment

v2025 Considerations

  • BI-RADS v2025 maintains nipple involvement as a named associated feature, emphasizing that it requires definitive abnormal enhancement contiguous with tumor
  • The distinction between nipple involvement (tumor extension) and nipple retraction (architectural distortion without direct invasion) remains a key reporting element in the v2025 lexicon